bioRxivCancer BiologyPreprint
Musashi-2 (MSI2) regulation of DNA damage response in lung cancer
I. Bychkov, A. Deneka, I. Topchu, R. P. Pangeni, C. Lengner, J. Karanicolas, E. A. Golemis, P. Makhov, Y. Boumber
Abstract
Lung cancer is one of the most common types of cancers worldwide. Non-small cell lung cancer (NSCLC), typically caused by KRAS and TP53 driver mutations, represents the majority of all new lung cancer diagnoses. Overexpression of the RNA-binding protein (RBP) Musashi-2 (MSI2) has been associated with NSCLC progression. To investigate the role of MSI2 in NSCLC development, we compared the tumorigenesis in mice with lung-specific Kras-activating mutation and Trp53 deletion, with and without Msi2 deletion (KP versus KPM2 mice). KPM2 mice showed decreased lung tumorigenesis in comparison with KP mice what supports published data. In addition, using cell lines from KP and KPM2 tumors, and human NSCLC cell lines, we found that MSI2 directly binds ATM/Atm mRNA and regulates its translation. MSI2 depletion impaired DNA damage response (DDR) signaling and sensitized human and murine NSCLC cells to treatment with PARP inhibitors in vitro and in vivo. Taken together, we conclude that MSI2 supports lung tumorigenesis, in part, by direct positive regulation of ATM protein expression and DDR. This adds the knowledge of MSI2 function in lung cancer development. Targeting MSI2 may be a promising strategy to treat lung cancer. SignificanceThis study shows the novel role of Musashi-2 as regulator of ATM expression and DDR in lung cancer.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- approach: wet-lab / biochemical assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Regulation of lung cancer initiation and progression by the stem cell determinant Musashi
Alison G. Barber, Cynthia M Quintero, … Tannishtha Reya·eLifePeer-reviewed·Mar 6, 2025
- Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer
I. Bychkov, I. Topchu, … Y. Boumber·bioRxiv·Mar 29, 2023
- NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity
K. Ingram, S. C. Samson, … M. C. Mendoza·bioRxiv·Mar 4, 2021
- RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
Alexander J. Pfeil, Tom Zhang, … Romel Somwar·Clinical Cancer ResearchPeer-reviewed·Jan 16, 2026
- Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
J. M. DeBlasi, A. Falzone, … G. M. DeNicola·bioRxiv·Aug 24, 2022
- Inhibiting TG2 sensitize lung cancer to radiotherapy through interfering TOPOIIα-mediated DNA repair